France's mid-sized biopharma company Ipsen recorded a sharp drop in 2011 net profits to €0.9 million ($1.2 million) as it booked charges relating to the ongoing restructuring of its business and increasing pricing pressure on its drug sales in France and other European markets.
Despite reporting a 5.7% increase in drug sales to €1.13 billion in 2011, and adjusted operating profits up by 9.6%...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?